Progress in the discovery and development of anticancer agents from marine cyanobacteria.

IF 10.2 1区 化学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Hendrik Luesch, Emma K Ellis, Qi-Yin Chen, Ranjala Ratnayake
{"title":"Progress in the discovery and development of anticancer agents from marine cyanobacteria.","authors":"Hendrik Luesch, Emma K Ellis, Qi-Yin Chen, Ranjala Ratnayake","doi":"10.1039/d4np00019f","DOIUrl":null,"url":null,"abstract":"<p><p>Covering 2010-April 2024There have been tremendous new discoveries and developments since 2010 in anticancer research based on marine cyanobacteria. Marine cyanobacteria are prolific sources of anticancer natural products, including the tubulin agents dolastatins 10 and 15 which were originally isolated from a mollusk that feeds on cyanobacteria. Decades of research have culminated in the approval of six antibody-drug conjugates (ADCs) and many ongoing clinical trials. Antibody conjugation has been enabling for several natural products, particularly cyanobacterial cytotoxins. Targeting tubulin dynamics has been a major strategy, leading to the discovery of the gatorbulin scaffold, acting on a new pharmacological site. Cyanobacterial compounds with different mechanisms of action (MOA), targeting novel or validated targets in a range of organelles, also show promise as anticancer agents. Important advances include the development of compounds with novel MOA, including apratoxin and coibamide A analogues, modulating cotranslational translocation at the level of Sec61 in the endoplasmic reticulum, largazole and santacruzamate A targeting class I histone deacetylases, and proteasome inhibitors based on carmaphycins, resembling the approved drug carfilzomib. The pipeline extends with SERCA inhibitors, mitochondrial cytotoxins and membrane-targeting agents, which have not yet advanced clinically since the biology is less understood and selectivity concerns remain to be addressed. In addition, efforts have also focused on the identification of chemosensitizing and antimetastatic agents. The review covers the state of current knowledge of marine cyanobacteria as anticancer agents with a focus on the mechanism, target identification and potential for drug development. We highlight the importance of solving the supply problem through chemical synthesis as well as illuminating the biological activity and in-depth mechanistic studies to increase the value of cyanobacterial natural products to catalyze their development.</p>","PeriodicalId":94,"journal":{"name":"Natural Product Reports","volume":" ","pages":""},"PeriodicalIF":10.2000,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11610234/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Natural Product Reports","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1039/d4np00019f","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Covering 2010-April 2024There have been tremendous new discoveries and developments since 2010 in anticancer research based on marine cyanobacteria. Marine cyanobacteria are prolific sources of anticancer natural products, including the tubulin agents dolastatins 10 and 15 which were originally isolated from a mollusk that feeds on cyanobacteria. Decades of research have culminated in the approval of six antibody-drug conjugates (ADCs) and many ongoing clinical trials. Antibody conjugation has been enabling for several natural products, particularly cyanobacterial cytotoxins. Targeting tubulin dynamics has been a major strategy, leading to the discovery of the gatorbulin scaffold, acting on a new pharmacological site. Cyanobacterial compounds with different mechanisms of action (MOA), targeting novel or validated targets in a range of organelles, also show promise as anticancer agents. Important advances include the development of compounds with novel MOA, including apratoxin and coibamide A analogues, modulating cotranslational translocation at the level of Sec61 in the endoplasmic reticulum, largazole and santacruzamate A targeting class I histone deacetylases, and proteasome inhibitors based on carmaphycins, resembling the approved drug carfilzomib. The pipeline extends with SERCA inhibitors, mitochondrial cytotoxins and membrane-targeting agents, which have not yet advanced clinically since the biology is less understood and selectivity concerns remain to be addressed. In addition, efforts have also focused on the identification of chemosensitizing and antimetastatic agents. The review covers the state of current knowledge of marine cyanobacteria as anticancer agents with a focus on the mechanism, target identification and potential for drug development. We highlight the importance of solving the supply problem through chemical synthesis as well as illuminating the biological activity and in-depth mechanistic studies to increase the value of cyanobacterial natural products to catalyze their development.

海洋蓝藻抗癌药物的发现与开发进展。
2010年以来,基于海洋蓝藻的抗癌研究取得了巨大的新发现和新进展。海洋蓝藻是抗癌天然产物的丰富来源,包括最初从以蓝藻为食的软体动物中分离出来的微管蛋白剂dolastatins 10和15。经过数十年的研究,六种抗体-药物偶联物(adc)获得批准,并进行了许多临床试验。抗体偶联已使几个天然产品,特别是蓝藻细胞毒素。靶向微管蛋白动力学一直是一个主要的策略,导致gatorbulin支架的发现,作用于一个新的药理学位点。具有不同作用机制(MOA)的蓝藻化合物,针对一系列细胞器中的新靶点或经过验证的靶点,也显示出抗癌药物的前景。重要的进展包括开发具有新型MOA的化合物,包括阿帕托毒素和coibamide A类似物,在内质网Sec61水平上调节共翻译易位,largazole和santacruzamate A靶向I类组蛋白去乙酰化酶,以及基于carmaphycin的蛋白酶体抑制剂,类似于已批准的药物carfilzomib。目前,SERCA抑制剂、线粒体细胞毒素和膜靶向药物还没有进入临床阶段,因为对这些药物的生物学特性了解较少,选择性问题仍有待解决。此外,努力也集中在鉴定化学增敏剂和抗转移剂。综述了海洋蓝藻作为抗癌药物的现状,重点介绍了其作用机制、靶点鉴定和药物开发潜力。我们强调通过化学合成解决供应问题的重要性,以及阐明生物活性和深入的机制研究,以增加蓝藻天然产物的价值,以催化其发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Natural Product Reports
Natural Product Reports 化学-生化与分子生物学
CiteScore
21.20
自引率
3.40%
发文量
127
审稿时长
1.7 months
期刊介绍: Natural Product Reports (NPR) serves as a pivotal critical review journal propelling advancements in all facets of natural products research, encompassing isolation, structural and stereochemical determination, biosynthesis, biological activity, and synthesis. With a broad scope, NPR extends its influence into the wider bioinorganic, bioorganic, and chemical biology communities. Covering areas such as enzymology, nucleic acids, genetics, chemical ecology, carbohydrates, primary and secondary metabolism, and analytical techniques, the journal provides insightful articles focusing on key developments shaping the field, rather than offering exhaustive overviews of all results. NPR encourages authors to infuse their perspectives on developments, trends, and future directions, fostering a dynamic exchange of ideas within the natural products research community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信